Get the Stockscreener App
43.24
0.12%
0.05
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $43.24, with a volume of 10.35M.
It is up +0.12% in the last 24 hours and down -5.40% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$43.19
Open:
$43.5
24h Volume:
10.35M
Relative Volume:
0.89
Market Cap:
$191.07B
Revenue:
$50.91B
Net Income/Loss:
$18.95B
P/E Ratio:
10.15
EPS:
4.261
Net Cash Flow:
$1.92B
1W Performance:
+0.39%
1M Performance:
-5.40%
6M Performance:
+15.46%
1Y Performance:
-30.09%
1-Day Range:
$42.78
$43.54
1-Week Range:
$41.47
$43.71
52-Week Range:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
43.24 | 190.32B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,152.93 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.99 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.96 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.87 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
140.37 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-18-26 | Initiated | Bernstein | Outperform |
| Mar-10-26 | Downgrade | TD Cowen | Buy → Hold |
| Mar-03-26 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-02-26 | Downgrade | Goldman | Buy → Neutral |
| Feb-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-24-26 | Downgrade | Kepler | Buy → Hold |
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk stock extends buyback as trial updates and obesity growth shape outlook - ad-hoc-news.de
Novo Nordisk (NYSE: NVO) has bought back 32M shares, with its 12‑month repurchase plan still running - Stock Titan
Novo Nordisk stock heads into the open after a 2.3% slide - ad-hoc-news.de
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? - The Motley Fool
Novo Nordisk stock falls as heart drug trials are halted despite pediatric obesity win - AD HOC NEWS
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk trial shows semaglutide helped 40% of children - Investing.com
Weekly Recap: Oral Wegovy launch in Germany and DKK8.7077bn buyback - TradingView
Novo Nordisk stock dips as Wegovy pill launch in Germany reshapes obesity market - AD HOC NEWS
European ADRs Push Higher In Wednesday Session Led By ING, IHG, And Novo Nordisk - foreignpolicyjournal.com
From hunger to obesity: Developing world faces growing threat to child health By Reuters - Investing.com
European ADRs Inched Higher As Healthcare Led Gains - Finimize
Novo Nordisk stock reacts to downgrade as oral obesity push advances in Asia - ad-hoc-news.de
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Novo Nordisk stock softens after Q2 upgrade and dividend payout - ad-hoc-news.de
Weekly Recap: DKK11.2bn B-share buyback and Wegovy UK/UAE uptake - TradingView
Novo Nordisk stock firms as new Wegovy pill study follows raised 2026 outlook - ad-hoc-news.de
Novo Nordisk Shares (NYSE:NVO) Gain 1.9% as $50 Medicare Wegovy Access Trial Challenges Pricing - ts2.tech
Novo Nordisk stock steadies after Q2 growth as buyback milestone is reached - Ad-hoc-news.de
Novo Nordisk stock benefits as France moves to reimburse Wegovy and new obesity trial begins - Ad-hoc-news.de
Novo Nordisk stock holds gains as obesity drug coverage in France supports long-term demand - Ad-hoc-news.de
Novo Nordisk stock steadies after Q2 2026 guidance raise and obesity pill volatility - Ad-hoc-news.de
Weekly Recap: Berenberg cuts NOVO_B and court orders Sun Pharma approval - TradingView
Novo Nordisk (NVO) Sues A Rival Over Obesity Drug Advertising Claims - Sahm
Novo Nordisk stock slips as obesity battle with Lilly and broker downgrade weigh on valuation - Ad-hoc-news.de
Novo Nordisk stock slips after Berenberg downgrade as guidance and competition reshape the outlook - Ad-hoc-news.de
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Why Does Novo Nordisk (NYSE:NVO) Matter to S&P 500 Healthcare? - Kalkine Media
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Sahm
EBITDA per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Revenue Breakdown – BCBA:NVO.CI - TradingView
Preferred dividends of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B - TradingView
Novo Nordisk NVO: $47.26 After Guidance Raise, Bull $64 - FinanceFeeds
Novo Nordisk Share Price Forecast | Q2 Earnings, Raised Guidance - Capital.com
Novo Nordisk's Track Record of Internal Innovation Supports a Wide Moat, but Diversification Needed - Morningstar
Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen - TechStock²
Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook - Finansavisen
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 - Finansavisen
Novo Nordisk (NYSE: NVO) updates DKK 7,533,256,457 share repurchases - Stock Titan
Weight loss stock wars: Key metrics to watch in Eli Lilly and Novo Nordisk results - Investing.com
Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study - Sahm
European ADRs Slipped In US Trading Friday Morning - Finimize
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation - Finansavisen
Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance - ts2.tech
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):